Safety, Dosimetry and Treatment Response of 177Lu-JH04 in Patients with FAP-Positive Tumors

Description:

This is a pilot study to assess the dosimetry, toxicity and response of , a new FAP-targeted radiopharmaceutical, in patients with FAP-Positive Tumors. All patients underwent 68Ga-FAPI PET/CT for selection and were successively divided into three groups of 3 people each.The three groups received successively an approximately 3.70 GBq (100 mCi), 5.55 GBq (150 mCi) and 7.40 GBq (200 mCi) of 177Lu-JH04 up to 4 cycles.